Premium
K orean medication algorithm for bipolar disorder: Second revision
Author(s) -
Shin Young Chul,
Min Kyung Joon,
Yoon BoHyun,
Kim Won,
Jon DukIn,
Seo JeongSeok,
Woo Young Sup,
Lee Jung Goo,
Bahk WonMyong
Publication year - 2013
Publication title -
asia‐pacific psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.654
H-Index - 21
eISSN - 1758-5872
pISSN - 1758-5864
DOI - 10.1111/appy.12062
Subject(s) - aripiprazole , quetiapine , lamotrigine , bipolar disorder , olanzapine , psychiatry , psychotic depression , depression (economics) , medicine , bipolar ii disorder , atypical antipsychotic , lithium (medication) , mood stabilizer , psychology , antipsychotic , schizophrenia (object oriented programming) , epilepsy , psychosis , economics , macroeconomics
The F easibility S tudy of the K orean M edication A lgorithm P roject for B ipolar D isorder 2002 ( KMAP‐BP 2002) revealed its clinical usefulness in 2005. Since much more data had become available since 2002, it was revised in 2006 as KMAP‐BP 2006. For the same reason, revision of KMAP‐BP 2006 is now necessary. Methods The questionnaire, amended on the basis of KMAP‐BP 2006 and new data, was sent to 94 experts, 65 of whom replied. Results I n an acute manic episode, a combination of a mood stabilizer ( MS ) with an atypical antipsychotic ( AAP ) is recommended as first‐line strategy. Monotherapy with MS is first‐line in a hypomanic episode. Triple combination of a MS , an AAP , and an antidepressant ( AD ), is the first‐line strategy in non‐psychotic severe depression. Also MS + AAP and MS + AD are recommended as first‐line. In psychotic bipolar depression, MS + AAP + AD , MS + AAP and AAP + AD are first‐line strategies. In bipolar depression, lithium, lamotrigine and valproic acid are selected as first‐line MS and quetiapine, olanzapine and aripiprazole are preferred antipsychotics. In maintenance treatment, a combination of MS with AAP and monotherapy of MS are recommended as first‐line. Discussion I n treating bipolar disorder, even the first step of treatment, the expert consensus has changed from our studies in 2002 and 2006.